Under the auspices of the Scottish Audit of Gastric and Esophageal Cancer, a group of researchers in Scotland, lead by Dr K Park, investigated treatment techniques, complications, and survival in a population-based cohort of patients undergoing endoscopic palliative therapy for esophageal or gastric cancer.
In this prospective study, the researchers identified a total of 948 patients undergoing endoscopic palliative therapy and followed them for a minimum of 1 year.
|Expandable metal stent placement and LASER were the most frequently used treatments|
Expandable metal stent placement was used in 506 patients and LASER in117 patients. These were the most frequently used treatment options.
Stent placement was more common for grade 3 or 4 dysphagia.
Delivery of endoscopic palliative therapy varied by region of residence (from 18% to 38% of patients) but not by deprivation category.
Doctors treating the patients reported complications in 16% of patients.
The researchers recorded an overall survival of 40% at 6 months, 17% at 12 months, and 10% at 18 months.
Dr Park concluded, "These data define the reality of endoscopic palliative therapy for patients with advanced esophageal or gastric cancer and provide a baseline against which future improvements in care can be measured."